+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations
D

Actively Recruiting

Researchers are analyzing health data from Germany collected between 2009 and 2024 to understand how common certain eye diseases are and how their occurrence has changed over time. The diseases studied include neovascular age-related macular degeneration nAMD, diabetic macular edema DME, and retinal vein occlusion RVO. The study aims to compare data from two large health datasets, FDZ and FDGP, and to explore how factors such as age, other health issues, and medications influence these diseases. The study observes groups of people diagnosed with nAMD, DME, or RVO and examines how many receive treatment with anti-VEGF medications, which are used to slow or prevent vision loss. This is an observational study, meaning it looks at existing health records and treatment patterns without assigning any new treatments. Participants are grouped into cohorts based on their diagnosis to compare disease patterns and treatment use. Participants health data will be reviewed to measure how often new cases occur incidence and how many people have these eye diseases at a given time prevalence in Germany. Researchers will also analyze treatment rates with anti-VEGF drugs and consider demographic and health factors affecting these diseases. The study is sponsored by Bayer and aims to provide a clearer picture of eye disease impact and management over 15 years.

Age: 18Years +All Genders
1 location
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations
C

Actively Recruiting

Triple negative breast cancer TNBC is a type of breast cancer that lacks certain receptors and tends to have a poor prognosis and aggressive behavior. The study focuses on patients with low-risk, early-stage TNBC stage I-II node-negative who generally have better outcomes, but still face significant clinical challenges. Researchers are evaluating neoadjuvant therapies to improve treatment strategies for this group, especially comparing sacituzumab govitecan alone versus its combination with pembrolizumab. Participants will receive neoadjuvant treatment for 12 weeks, either sacituzumab govitecan alone or combined with pembrolizumab. Sacituzumab govitecan is given intravenously at 10 mgkg on Days 1 and 8 every 21 days, while pembrolizumab is administered intravenously at 200 mg every three weeks. Depending on their response after 12 weeks, some patients may continue treatment for an additional 6 weeks before surgery. Patients who achieve a complete response may not require further systemic treatment, while those with residual disease may receive additional chemotherapy as decided by their investigator. Throughout the study, participants will be closely monitored with various assessments including pathological evaluation at surgery and invasive disease-free survival measured after three years. Other outcomes include overall survival and quality of life assessments. Safety and response will be regularly evaluated to guide treatment decisions. The trial aims to enroll adult women with early-stage TNBC and will continue through September 2029, with detailed follow-up planned to capture long-term outcomes.

Age: 18Years +FEMALEPhase 3
43 locations
P

Actively Recruiting

Researchers are investigating the effects of additional chemotherapy treatment after surgery or ablation in patients with metastatic colorectal cancer whose tumor lesions have been definitively treated. This phase III, open-label, randomized, controlled trial aims to compare the effectiveness, quality of life, and safety of mFOLFOXIRImFOLFOX-6 chemotherapy against active follow-up without additional chemotherapy. The study also includes a translational research component to analyze tumor biopsies and blood samples for disease relapse markers. Patients are assigned randomly in a 21 ratio to receive either active chemotherapy mFOLFOXIRI, mFOLFOX6, FOLFIRI, or CAPOX for up to six months or structured follow-up without chemotherapy. Chemotherapy regimens involve intravenous infusions and oral medications administered in cycles every two or three weeks, with a maximum of 12 cycles for most treatments. After treatment or follow-up, participants continue with structured monitoring for up to five years. Participants undergo re-assessments every three months during the first two years, including CT or MRI scans of the thorax and abdomen, blood tests, and quality of life evaluations to detect disease relapse. After two years without relapse, follow-up intervals extend to every six months. The primary outcome measured is progression-free survival at 24 months, with secondary outcomes including overall survival, lesion control, adverse events, and quality of life monitored for up to five years following randomization.

Age: 18Years +All GendersPhase 3
79 locations
L

Actively Recruiting

Researchers are investigating the real-world use and effects of ovarian function suppression OFS combined with endocrine therapy in pre- and perimenopausal women with breast cancer who have low genomic risk according to MammaPrint testing. The study aims to understand differences in treatment outcomes based on menopausal status, chemotherapy use, and endocrine therapies, with a focus on adherence and quality of life over time. This observational registry will collect data to provide insights into treatment paths, outcomes, and factors influencing prognosis in these patients. Participants receive standard-of-care endocrine therapy with or without ovarian suppression and may have received chemotherapy based on clinical decisions and genomic risk assessments. The registry observes various treatment approaches in a real-world setting, including management of ovarian function, and follows patients for up to 10 years. Quality of life assessments occur regularly during the first five years, and treatment adherence is monitored throughout the study period. During the study, participants medical data including baseline characteristics, treatment details, relapse information, and quality of life questionnaires will be collected at multiple time points. Researchers will evaluate outcomes such as distant recurrence-free interval, disease-free survival, overall survival, and endocrine response over 5 to 10 years. The long-term follow-up allows for detailed monitoring of treatment adherence and correlation of genomic and clinicopathological markers with patient outcomes.

Age: 18Years - 60YearsFEMALE
71 locations
O

Actively Recruiting

This observational study investigates the use of hydrotalcite, marketed as Talcid, to relieve acid-related symptoms caused by acid rebound after stopping long-term proton pump inhibitor PPI therapy that is no longer indicated. PPIs are commonly prescribed to reduce stomach acid for conditions like heartburn and ulcers, but stopping long-term use can lead to symptoms such as heartburn returning. The study focuses on adults in Germany who have discontinued non-indicated PPI therapy and are experiencing these rebound symptoms. Participants will use hydrotalcite as an on-demand treatment over a four-week period when symptoms occur. They will take Talcid chewable tablets and record symptom relief, the time it takes for relief, and overall satisfaction. Doctors will also evaluate the treatments suitability, tolerability, and effectiveness. The study does not involve randomization or intervention but collects real-world data from about twenty sites. During the study, participants will complete standardized questionnaires to report their symptoms and satisfaction. Researchers will measure how many participants successfully stop PPI use during the four weeks and assess relief from heartburn, reflux, pain, fullness, and nausea. Quality of life changes and investigators ratings of the treatment will also be recorded. The study plans to enroll around 167 participants to ensure about 100 complete the study by October 2026.

Age: 18Years +All Genders
2 locations
R

Actively Recruiting

Ulcerative colitis UC is an inflammatory bowel disease causing inflammation and bleeding in the rectum and colon. This study evaluates the change in disease activity in adult participants with moderate to severe UC who are treated with risankizumab in real-world clinical practice. The study is observational and will include about 200 participants across multiple sites in Germany and Austria. Participants will receive risankizumab as prescribed by their physicians according to routine clinical care and local guidelines. The treatment is not assigned by the study team but follows the physicians decision. Participants will be observed and followed for up to 52 weeks while receiving this treatment under normal clinical conditions. During the study, participants will attend regular visits at hospitals or clinics as part of their routine care. There will be no additional burden beyond regular clinical visits. Researchers will measure the percentage of participants achieving symptomatic remission based on the Partial Adapted Mayo Score over approximately 52 weeks. Safety and effectiveness of risankizumab will be monitored throughout the study period.

Age: 18Years +All Genders
57 locations

1-10 of 12

1